Homburger advised ADC Therapeutics in connection with the amendment of its royalty purchase agreement with entities managed by HealthCare Royalty. As consideration for reducing change of control payment from USD 750 m to USD 150 m to
Tags :ADC
Lenz & Staehelin advised the underwriters on ADC’s sale of 13.4 million shares of its common stock and pre-funded warrants to purchase 8.1 million shares of its common stock in an underwritten offering for gross proceeds
Lenz & Staehelin has advised investment bank Jefferies as underwriter in the public offering of shares of the Lausanne based ADC Therapeutics, a commercial-stage biotechnology company helping to improve the lives of those affected by
ADC Therapeutics, a commercial-stage biotechnology company headquartered in Lausanne, announced the pricing of an underwritten offering of 12 m ADCT shares currently owned by A.T. Holdings II, an affiliate of Auven Therapeutics Holding, at a
